Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

European Journal of Health Economics

Volumn 15, Issue 1, 2014, Pages 69-82

  Samyshkin, Yevgeniy ^a   Kotchie, Robert W ^a   Mörk, Ann Christin ^b   Briggs, Andrew H ^c   Bateman, Eric D ^d  

^a IQVIA   (United States)

^b Takeda Pharmaceuticals International GmbH   (Switzerland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Chronic obstructive pulmonary disease; COPD; Cost effectiveness analysis; Exacerbations; Roflumilast

Indexed keywords

BRONCHODILATING AGENT; LONG ACTING DRUG; PREDNISOLONE; ROFLUMILAST;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FATALITY; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LIFE EXPECTANCY; LIFESPAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; UNITED KINGDOM; VERY ELDERLY;

AGE FACTORS; AGED; AMINOPYRIDINES; BENZAMIDES; BRONCHITIS; BRONCHODILATOR AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; CYCLOPROPANES; DELAYED-ACTION PREPARATIONS; FEMALE; GREAT BRITAIN; HEALTH SERVICES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; RESPIRATORY FUNCTION TESTS;

EID: 84898596300     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0456-5     Document Type: Article

References (39)

1. Halbert, R.J., Natoli, J.L., Gano, A., Badamgarav, E., Buist, A.S., Mannino, D.M.: Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 28(3), 523-532 (2006)
2. Global Strategy for the Diagnosis, Management, and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2011)
3. Jones, P.W.: Activity limitation and quality of life in COPD. COPD 4(3), 273-278 (2007)
4. Roche, N.: Activity limitation: a major consequence of dyspnoea in COPD. Eur. Respir.Rev. 18(112), 54-57 (2009)
5. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Health and Clinical Excellence (2010)
6. Calverley, P.M., Rabe, K.F., Goehring, U.M., Kristiansen, S., Fabbri, L.M., Martinez, F.J.: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685-694 (2009)
7. FitzGerald, J.M., Haddon, J.M., Bradly-Kennedy, C., Kuramoto, L., Ford, G.T.: Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J. 14(3), 145-152 (2007)
8. Oostenbrink, J.B., Rutten-van Mölken, M.P.: Resource use and risk factors in high-cost exacerbations of COPD. Respir. Med. 98(9), 883-891 (2004)
9. Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A.: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57(10), 847-852 (2002)
10. Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax 64(10), 894-900 (2009)
11. Guerra, S., Sherrill, D.L., Venker, C., Ceccato, C.M., Halonen, M., Martinez, F.D.: Morbidity and mortality associated with the restrictive spirometric pattern: a longitudinal study. Thorax 65(6), 499-504 (2010)
12. Oostenbrink, J.B., Rutten-van Mölken, M.P., Monz, B.U., Fitz- Gerald, J.M.: Probabilistic Markov model to assess the costeffectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 8(1), 32-46 (2005)
13. Rutten-van Mölken, M.P., Lee, T.A.: Economic modeling in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 3(7), 630-634 (2006)
14. European Public Assessment Report (EPAR) for Daxas. Product information. 28/03/2011 Daxas -EMEA/H/C/001179-IB/0002.20-7-2010 (2010)
15. Bateman, E.D., Rabe, K.F., Calverley, P.M., Goehring, U.M., Brose, M., Bredenbröker, D., Fabbri, L.M.: Roflumilast with long-acting ß2 agonists for COPD: influence of exacerbation history. Eur. Respir. J. 38(3), 553-560 (2011)
16. Selected subgroup analyses based on data from Studies M2-124 and M2-125 in subpopulation of LABA-treated patients and subpopulation of LABA-treated patients with at least two COPD exacerbations in the previous year. 16-7-2010. Nycomed International Management GmbH (2010)
17. Crapo, R.O., Morris, A.H., Gardner, R.M.: Reference spirometric values using techniques and equipment that meet ATS recommendations. Am. Rev. Respir. Dis. 123(6), 659-664 (1981)
18. Scanlon, P.D., Connett, J.E., Waller, L.A., Altose, M.D., Bailey, W.C., Buist, A.S.: Smoking cessation and lung function in mild-tomoderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 161, 381-390 (2000)
19. Statistical report. Effect of roflumilast on exacerbation rates in based on data from studies M2-124 and M2-125 in subpopulation of LABA-treated patients. Nycomed International Management GmbH (2009)
20. Report of the 2008 National COPD Audit: The Royal College of Physicians and the British Thoracic Society (2008)
21. Hoogendoorn, M., Hoogenveen, R.T., Rutten-van Mölken, M.P., Vestbo, J., Feenstra, T.L.: Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur. Respir. J. 37(3), 508-515 (2011)
22. Ekberg-Aronsson, M., Pehrsson, K., Nilsson, J.A., Nilsson, P.M., Lofdahl, C.G.: Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir. Res. 6(1), 98 (2005). doi:10.1186/1465-9921-6-98
23. Rutten-van Mölken, M.P., Hoogendoorn, M., Lamers, L.M.: Holistic preferences for 1-year health profiles describing fluctuations in health: the case of chronic obstructive pulmonary disease. Pharmacoeconomics 27(6), 465-477 (2009)
24. British National Formulary. British Medical Association and Royal Pharmaceutical Society, London (2010)
25. NHS reference costs 2009-2010. 13-1-2011. UK Department of Health (2011)
26. Claxton, K., Sculpher, M., McCabe, C., Briggs, A., Akehurst, R., Buxton, M., Brazier, J., O'Hagan, T.: Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 14(4), 339-347 (2005)
27. Borg, S., Ericsson, A., Wedzicha, J., Gulsvik, A., Lundbäck, B., Donaldson, G.C., Sullivan, S.D.: A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health 7(2), 153-167 (2004)
28. Earnshaw, S.R., Wilson, M.R., Dalal, A.A., Chambers, M.G., Jhingran, P., Stanford, R., Mapel, D.W.: Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respir. Med. 103(1), 12-21 (2009)
29. Oba, Y.: Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Am. J. Manag. Care 15(4), 226-232 (2009)
30. Spencer, M., Briggs, A.H., Grossman, R.F., Rance, L.: Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 23(6), 619-637 (2005)
31. Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., Yates, J.C., Vestbo, J., TORCH investigators.: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775-789 (2007)
32. Hanania, N.A.: The impact of inhaled corticosteroid and longacting beta-agonist combination therapy on outcomes in COPD. Pulm. Pharmacol. Ther. 21(3), 540-550 (2008)
33. Tashkin, D., Celli, B., Kesten, S., Lystig, T., Decramer, M.: Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir. Med. 104(10), 1495-1504 (2010)
34. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M., UPLIFT Study Investigators.: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 359(15), 1543-1554 (2008)
35. Martinez, F.J., Rabe, K.F., Goehring, U.M., Lakkis, H., Rowe, P., Palm, U.: Roflumilast prolongs time to first and subsequent exacerbations in patients with severe to very severe COPD. In: American Thoracic Society International Conference. ATS-2011. Denver, Colorado, USA. 13-5-2011 (2011)
36. Mills, E.J., Druyts. E., Ghement, I., Puhan M.A.: Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis. Clin. Epidemiol. 3, 107-129 (2011)
37. Hertel, N., Kotchie, R.W., Samyshkin, Y., Radford, M., Humphreys, S., Jameson, K.: Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 7, 183-199 (2012)
38. Rabe, K.F.: Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J. Pharmacol. 163(1), 53-67 (2011)
39. Personal Social Services Research Unit, UK. Unit Costs of Health and Social Care 2009. http://www.pssru.ac.uk/archive/pdf/uc/ uc2009/uc2009.pdf (2009)